| 选择性COX-2抑制剂的安全性评估 |
| |
| 引用本文： | 鄢琳,井春梅,周杰明,肖爱丽,程刚,汤韧.选择性COX-2抑制剂的安全性评估[J].中国药物警戒,2005,2(1):16-20. |
| |
| 作者姓名： | 鄢琳 井春梅 周杰明 肖爱丽 程刚 汤韧 |
| |
| 作者单位： | 国家食品药品监督管理局药品评价中心,北京,100061 |
| |
| 摘 要： | 概述选择性COX-2抑制剂的临床特点及其胃肠道、心血管和肾脏的安全性,分析药物产生非胃肠道不良反应的机制,为此类药物临床合理应用提供依据.
|
| 关 键 词： | COX-2抑制剂 安全性 罗非昔布 塞来昔布 |
Safety Assessment of Selective COX-2 Inhlbitors |
| |
| YAN Lin,JING Chun-mei,ZHOU Jie-ming,XIAO Ai-li,CHENG Gang,TANG Ren.Safety Assessment of Selective COX-2 Inhlbitors[J].Chinese JOurnal of Pharmacovigilance,2005,2(1):16-20. |
| |
| Authors: | YAN Lin JING Chun-mei ZHOU Jie-ming XIAO Ai-li CHENG Gang TANG Ren |
| |
| Institution: | Beijng 100061 |
| |
| Abstract: | Summarize the clinical characteristics of selective COX-2 inhibitors, and the gastrointestinal, cardiovascular and renal toxicity associated with these drugs. Analyze the mechanism of non-gastrointestinal adverse reactions of selective COX-2 inhibitors and provid the evidence for drug rational use. |
| |
| Keywords: | COX-2 Inhibitors Safety Rofecoxib Celecoxib |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
